What question did this study set out to answer?

To assess the comparative risk of major adverse cardiovascular events across tyrosine kinase inhibitors in chronic myeloid leukemia patients.

December 8, 2025BloodOpen Access

Major adverse cardiovascular events (MACE) in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A target trial emulation study

View Full Paper

Ask AI

Bookmark

Authors

HDHenyah W. DardirNortheast Ohio Medical University SBSophia BaldermanCleveland Clinic AAAnjali S. AdvaniCleveland Clinic

Discussion

Member takes

Implication

Target trial emulation found increased major adverse cardiovascular event risk with second/third-generation TKIs compared to imatinib in chronic myeloid leukemia patients.

Key Points

To assess the comparative risk of major adverse cardiovascular events across tyrosine kinase inhibitors in chronic myeloid leukemia patients.
Emulated five target trials using TriNetX EHR network across 68 healthcare systems.
Analyzed adults with BCR/ABL+ CML initiating a TKI between 2013-2024.
Primary trial compared imatinib with pooled second/third-generation TKIs; adjusted for 59 covariates using propensity score matching.
Second/third-generation TKIs associated with 1.73 times higher risk of composite MACE compared to imatinib.
Increased risks for myocardial infarction (HR 2.21) and stroke (HR 1.55) compared to imatinib.
Higher cholesterol levels were observed over time among TKI users, indicating more atherogenic lipid profiles.

Cite This Study

Dardir et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3c3 https://doi.org/10.1182/blood-2025-4627

View Full Paper

Ask AI

Bookmark

Implication

Target trial emulation found increased major adverse cardiovascular event risk with second/third-generation TKIs compared to imatinib in chronic myeloid leukemia patients.

Major adverse cardiovascular events (MACE) in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A target trial emulation study

Discussion

Member takes

Implication

Key Points

Cite This Study

Major adverse cardiovascular events (MACE) in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A target trial emulation study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider